Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
97% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MDXG: No Debt )
MDXG' s 10-Year Cash to Debt Range
Min: 0.6   Max: No Debt
Current: No Debt

Equity to Asset 0.82
MDXG's Equity to Asset is ranked higher than
88% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MDXG: 0.82 )
MDXG' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.87
Current: 0.82

0.44
0.87
Interest Coverage No Debt
MDXG's Interest Coverage is ranked higher than
76% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. MDXG: No Debt )
MDXG' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 6
Z-Score: 32.91
M-Score: -2.41
WACC vs ROIC
16.38%
18.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 6.01
MDXG's Operating margin (%) is ranked higher than
75% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 6.11 vs. MDXG: 6.01 )
MDXG' s 10-Year Operating margin (%) Range
Min: -1334.98   Max: 6.01
Current: 6.01

-1334.98
6.01
Net-margin (%) 5.26
MDXG's Net-margin (%) is ranked higher than
77% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 4.39 vs. MDXG: 5.26 )
MDXG' s 10-Year Net-margin (%) Range
Min: -1447.4   Max: 5.26
Current: 5.26

-1447.4
5.26
ROE (%) 7.88
MDXG's ROE (%) is ranked higher than
78% of the 448 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. MDXG: 7.88 )
MDXG' s 10-Year ROE (%) Range
Min: -276.61   Max: 7.64
Current: 7.88

-276.61
7.64
ROA (%) 6.69
MDXG's ROA (%) is ranked higher than
84% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. MDXG: 6.69 )
MDXG' s 10-Year ROA (%) Range
Min: -557.14   Max: 6.41
Current: 6.69

-557.14
6.41
ROC (Joel Greenblatt) (%) 36.15
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. MDXG: 36.15 )
MDXG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2458.54   Max: 39.25
Current: 36.15

-2458.54
39.25
Revenue Growth (3Y)(%) 111.50
MDXG's Revenue Growth (3Y)(%) is ranked higher than
100% of the 350 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. MDXG: 111.50 )
MDXG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 293.6
Current: 111.5

0
293.6
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MDXG Guru Trades in Q1 2014

Steven Cohen 1,035,000 sh (+15.26%)
Caxton Associates Sold Out
Jim Simons Sold Out
» More
Q2 2014

MDXG Guru Trades in Q2 2014

Jim Simons 179,900 sh (New)
Steven Cohen 906,800 sh (unchged)
» More
Q3 2014

MDXG Guru Trades in Q3 2014

Joel Greenblatt 17,878 sh (New)
Jim Simons 251,000 sh (+39.52%)
Steven Cohen 825,000 sh (-9.02%)
» More
Q4 2014

MDXG Guru Trades in Q4 2014

Paul Tudor Jones 19,098 sh (New)
Joel Greenblatt 36,045 sh (+101.62%)
Steven Cohen Sold Out
Jim Simons 198,172 sh (-21.05%)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 201.60
MDXG's P/E(ttm) is ranked higher than
68% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 137.90 vs. MDXG: 201.60 )
MDXG' s 10-Year P/E(ttm) Range
Min: 153.87   Max: 1843.33
Current: 201.6

153.87
1843.33
Forward P/E 33.33
MDXG's Forward P/E is ranked higher than
80% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 33.33 )
N/A
PE(NRI) 197.80
MDXG's PE(NRI) is ranked higher than
71% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 115.50 vs. MDXG: 197.80 )
MDXG' s 10-Year PE(NRI) Range
Min: 163.1   Max: 1106
Current: 197.8

163.1
1106
P/B 12.50
MDXG's P/B is ranked lower than
55% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. MDXG: 12.50 )
MDXG' s 10-Year P/B Range
Min: 5.5   Max: 21.82
Current: 12.5

5.5
21.82
P/S 10.23
MDXG's P/S is ranked lower than
57% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.71 vs. MDXG: 10.23 )
MDXG' s 10-Year P/S Range
Min: 6.84   Max: 148
Current: 10.23

6.84
148
PFCF 97.30
MDXG's PFCF is ranked higher than
75% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 97.30 )
MDXG' s 10-Year PFCF Range
Min: 74.14   Max: 221.2
Current: 97.3

74.14
221.2
POCF 70.64
MDXG's POCF is ranked higher than
72% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.76 vs. MDXG: 70.64 )
MDXG' s 10-Year POCF Range
Min: 58.25   Max: 372
Current: 70.64

58.25
372
EV-to-EBIT 141.11
MDXG's EV-to-EBIT is ranked higher than
69% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.34 vs. MDXG: 141.11 )
MDXG' s 10-Year EV-to-EBIT Range
Min: -299.1   Max: 1158.8
Current: 141.11

-299.1
1158.8
Current Ratio 4.66
MDXG's Current Ratio is ranked higher than
87% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. MDXG: 4.66 )
MDXG' s 10-Year Current Ratio Range
Min: 0.07   Max: 14
Current: 4.66

0.07
14
Quick Ratio 4.38
MDXG's Quick Ratio is ranked higher than
89% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. MDXG: 4.38 )
MDXG' s 10-Year Quick Ratio Range
Min: 0.07   Max: 14
Current: 4.38

0.07
14
Days Inventory 124.62
MDXG's Days Inventory is ranked higher than
77% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 165.69 vs. MDXG: 124.62 )
MDXG' s 10-Year Days Inventory Range
Min: 11.88   Max: 135.08
Current: 124.62

11.88
135.08
Days Sales Outstanding 82.35
MDXG's Days Sales Outstanding is ranked higher than
69% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.24 vs. MDXG: 82.35 )
MDXG' s 10-Year Days Sales Outstanding Range
Min: 74.94   Max: 103.26
Current: 82.35

74.94
103.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 35.60
MDXG's Price/Net Cash is ranked higher than
82% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 35.60 )
MDXG' s 10-Year Price/Net Cash Range
Min: 27.31   Max: 40.57
Current: 35.6

27.31
40.57
Price/Net Current Asset Value 20.90
MDXG's Price/Net Current Asset Value is ranked higher than
75% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 20.90 )
MDXG' s 10-Year Price/Net Current Asset Value Range
Min: 16.81   Max: 135
Current: 20.9

16.81
135
Price/Tangible Book 15.30
MDXG's Price/Tangible Book is ranked higher than
55% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.75 vs. MDXG: 15.30 )
MDXG' s 10-Year Price/Tangible Book Range
Min: 10.57   Max: 237.5
Current: 15.3

10.57
237.5
Price/DCF (Projected) 26.70
MDXG's Price/DCF (Projected) is ranked higher than
76% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 26.70 )
MDXG' s 10-Year Price/DCF (Projected) Range
Min: 28.83   Max: 28.83
Current: 26.7

Price/Median PS Value 0.80
MDXG's Price/Median PS Value is ranked higher than
86% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. MDXG: 0.80 )
MDXG' s 10-Year Price/Median PS Value Range
Min: 0.84   Max: 11.25
Current: 0.8

0.84
11.25
Price/Graham Number 11.20
MDXG's Price/Graham Number is ranked higher than
68% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 11.20 )
MDXG' s 10-Year Price/Graham Number Range
Min: 12.14   Max: 12.14
Current: 11.2

Earnings Yield (Greenblatt) 0.60
MDXG's Earnings Yield (Greenblatt) is ranked higher than
64% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. MDXG: 0.60 )
MDXG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.8
Current: 0.6

0.1
0.8

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany,
MiMedx Group, Inc. was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
SHAREHOLDER ALERT: Gainey McKenna & Egleston Reminds Investors of Class Action Against MiMedx Group,... Mar 27 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of MiMedx Group, Inc. of PENDENCY OF... Mar 25 2015
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of MiMedx Group, Inc. Of Upcoming... Mar 24 2015
Government Declines to Intervene in Action Against MiMedx Mar 23 2015
Government Declines to Intervene in Action Against MiMedx Mar 23 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in MiMedx... Mar 20 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Mar 17 2015
MiMedx to Present at 3rd Annual Regen Med Investor Day Mar 17 2015
MiMedx to Present at 3rd Annual Regen Med Investor Day Mar 17 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving MiMedx... Mar 17 2015
MiMedx To Present At Canaccord's 10th Annual Musculoskeletal Conference Mar 16 2015
MIMEDX GROUP, INC. Files SEC form 10-K, Annual Report Mar 13 2015
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Mar 11 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MiMedx Group, Inc. of PENDENCY OF... Mar 10 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in MiMedx... Mar 06 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Mar 04 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of MiMedx Group, Inc. of PENDENCY OF... Mar 02 2015
IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal... Feb 27 2015
MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit Feb 26 2015
MiMedx Group Inc Earnings Call scheduled for 10:30 am ET today Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK